A Comprehensive Monograph on Palifermin (Kepivance®): From Molecular Biology to Clinical Application

Executive Summary

Palifermin, marketed under the brand name Kepivance®, is a truncated recombinant human keratinocyte growth factor (KGF) representing a significant milestone in supportive oncology care. It is a biotech therapeutic produced in Escherichia coli and specifically engineered for enhanced stability. Its primary, narrowly defined indication is to decrease the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support, particularly with preparative regimens predicted to cause a high incidence of severe mucositis.

The mechanism of action of palifermin is rooted in its function as an agonist of the KGF receptor (FGFR2b), which is selectively expressed on epithelial cells. This interaction stimulates a cascade of cellular activities, including proliferation, differentiation, and the upregulation of cytoprotective mechanisms, effectively thickening and strengthening the mucosal barrier against the cytotoxic insults of chemotherapy and radiation.

The efficacy of palifermin was unequivocally established in a pivotal Phase 3 clinical trial, which demonstrated statistically significant and clinically meaningful reductions in the incidence, duration, and severity of severe OM, leading to decreased patient-reported soreness, reduced opioid use, and less need for parenteral nutrition. However, its efficacy is highly context-specific, with a lack of benefit observed in patients undergoing allogeneic stem cell transplantation or those receiving high-dose melphalan conditioning regimens.

The safety profile of palifermin is largely predictable and dominated by on-target pharmacological effects, such as transient skin rashes and oral sensory changes. The most significant safety concern is a theoretical potential for stimulating the growth of KGF receptor-expressing non-hematologic tumors, a warning that has constrained its clinical investigation and use in solid tumor settings.

Developed by Amgen and later acquired by Swedish Orphan Biovitrum (Sobi), palifermin's commercial history highlights the challenges facing highly effective but niche biologic drugs, including its eventual market withdrawal in the European Union for commercial reasons. Its place in therapy, supported by major clinical guidelines, is as a specialized, high-potency agent for a specific, high-risk patient population, complementing foundational strategies like basic oral care and cryotherapy. The pharmacoeconomic profile remains complex, with its value proposition being most evident in patient populations with the highest baseline risk for severe mucositis.

1.0 Introduction: Palifermin and the Clinical Challenge of Oral Mucositis

Oral mucositis (OM) stands as one of the most acute, distressing, and clinically significant toxicities associated with cancer treatment.[1] Affecting a substantial proportion of patients undergoing chemotherapy and/or radiation therapy, its incidence can reach 70-80% in high-risk populations.[1] The condition is characterized by painful, erythematous, and ulcerative lesions of the oral mucosa, which can extend throughout the oropharynx and the entire gastrointestinal tract.[2] The clinical consequences of severe OM are profound, leading to severe pain that often necessitates high doses of opioid analgesics, dysphagia that impairs nutritional intake and may require total parenteral nutrition (TPN), an increased risk of local and systemic infections due to the compromised mucosal barrier, and prolonged hospitalizations.[2] Critically, the severity of OM can become a dose-limiting toxicity, forcing interruptions or reductions in cancer therapy and potentially compromising treatment outcomes.[2] Patients consistently rate severe OM as one of the most debilitating side effects of their cancer treatment journey.[6]

The pathophysiology of OM is a complex biological cascade that has been described by a five-phase model: (1) an initiation phase, where chemotherapy or radiation induces DNA damage in the basal epithelial cells and generates reactive oxygen species (ROS); (2) a signaling and upregulation phase, where damaged cells release pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β); (3) a signal amplification phase, where these cytokines create a positive feedback loop, recruiting more inflammatory cells and exacerbating tissue damage; (4) an ulceration phase, marked by the loss of epithelial integrity, formation of painful lesions, and opportunistic microbial colonization; and (5) a healing phase, where epithelial cell proliferation and migration restore the mucosal barrier.[8]

For decades, the management of OM was largely palliative and supportive. Interventions focused on symptom control through pain management, nutritional support, and basic oral hygiene, but there was no established therapy capable of effectively preventing or treating the underlying pathology.[1] The development of palifermin, marketed as Kepivance®, marked a paradigm shift in this landscape. As the first and, for a long time, only agent approved by the U.S. Food and Drug Administration (FDA) specifically to decrease the incidence and duration of severe OM, palifermin introduced a targeted, pathobiology-driven prophylactic strategy.[4] By leveraging the biological activity of keratinocyte growth factor, it intervenes directly in the processes of epithelial damage and repair, representing a move from merely managing the consequences of mucositis to proactively mitigating its development and severity.

2.0 Molecular Profile and Mechanism of Action

Palifermin is a highly specific biologic agent engineered to harness the natural restorative power of keratinocyte growth factor for therapeutic benefit. Its molecular characteristics and mechanism of action are central to understanding both its efficacy and its distinct safety profile.

2.1 Drug Identity and Physicochemical Properties

Palifermin (DrugBank ID: DB00039; CAS Number: 162394-19-6) is a recombinant human keratinocyte growth factor (KGF), also known as fibroblast growth factor 7 (FGF-7).[15] It is classified as a biotech drug, specifically a protein-based therapy belonging to the pharmacologic class of mucocutaneous epithelial cell growth factors.[15]

The therapeutic protein is produced using recombinant DNA technology in an Escherichia coli expression system.[2] It is a water-soluble, non-glycosylated protein composed of a single 140-amino acid chain with a molecular weight of approximately 16.3 kilodaltons (kDa).[19] The empirical chemical formula is reported as

C721​H1142​N202​O204​S9​, with an average molecular weight of 16192.7 Da.[15] A key structural feature of palifermin is that it is a truncated form of the full-length, endogenous human KGF. Specifically, the first 23 N-terminal amino acids have been deleted. This modification was a deliberate act of rational drug design to enhance the protein's stability, making it a more viable therapeutic agent compared to the native protein.[16]

Table 2.1: Summary of Palifermin (Kepivance®) Drug Profile

| Attribute | Description | Source(s) |

| :--- | :--- | :--- |

| Generic Name | Palifermin | 15 |

| Brand Name | Kepivance® | 15 |

| DrugBank ID | DB00039 | 15 |

| CAS Number | 162394-19-6 | 16 |

| Type | Biotech | 15 |

| Biologic Classification | Protein Based Therapies; Recombinant Growth Factor | 15 |

| Molecular Formula | C721​H1142​N202​O204​S9​ | 15 |

| Average Molecular Weight | 16192.7 Da | 15 |

| Amino Acid Count | 140 | 15 |

| Key Structural Feature | Truncated form of human KGF (N-terminal 23 amino acids deleted) | 19 |

2.2 Mechanism of Action

Palifermin's therapeutic activity is a direct extension of the physiological role of endogenous KGF. As a paracrine-acting epithelial mitogen, KGF is naturally produced by mesenchymal cells and is upregulated in response to epithelial tissue injury.[2] Palifermin mimics and amplifies this protective and reparative process through a specific and multifactorial mechanism.

The drug functions as an agonist by binding with high affinity to the KGF receptor (KGFR).[15] This receptor is a specific splice variant of the Fibroblast Growth Factor Receptor 2, known as FGFR2b, which is expressed exclusively on the surface of epithelial cells.[23] These KGFR-expressing cells are abundant in many tissues that are vulnerable to damage from cancer therapies, including the tongue, buccal mucosa, esophagus, stomach, intestine, and salivary glands.[2]

Upon binding to the KGFR, palifermin triggers receptor dimerization and transphosphorylation of the intracellular tyrosine kinase domains. This activates a cascade of downstream intracellular signaling pathways, most notably the mitogen-activated protein kinase (MAPK) pathway.[17] This signaling cascade results in a coordinated cellular response characterized by several key effects:

• Stimulation of Proliferation, Differentiation, and Migration: Palifermin acts as a potent mitogen for epithelial cells, stimulating their growth and division. This leads to a measurable increase in the thickness of the mucosal epithelium, effectively strengthening the physical barrier against cytotoxic damage.[1] It also promotes the migration of epithelial cells to cover injured areas, accelerating the healing process.[24]
• Upregulation of Cytoprotection: The drug enhances the innate defense mechanisms of epithelial cells. It upregulates the expression of genes encoding for cytoprotective proteins and antioxidant enzymes that scavenge the damaging reactive oxygen species (ROS) produced during chemotherapy and radiotherapy.[2]
• Anti-inflammatory and Anti-apoptotic Effects: Palifermin modulates the local immune environment. It has been shown to stimulate the production of anti-inflammatory cytokines, such as interleukin-13 (IL-13), which can reduce levels of the pro-inflammatory cytokine TNF-α.[2] It also exerts anti-apoptotic effects, helping epithelial cells survive the toxic insult.[2]

The specificity of this mechanism is fundamental to palifermin's entire risk-benefit profile. Its targeted action on KGFR-expressing epithelial cells explains its potent protective effect on the mucosal lining of the gastrointestinal tract. However, this same specificity is the source of its primary safety concern. Because many solid tumors, particularly carcinomas, are of epithelial origin, they may also express the KGF receptor. Consequently, the very mechanism that provides the therapeutic benefit—the stimulation of epithelial cell growth—also creates a theoretical risk of promoting the growth of certain non-hematologic tumors.[2] This inherent duality has been a guiding principle in its clinical development, leading to its restricted indication and the significant warnings associated with its use.

3.0 Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical pharmacology of palifermin describes how the body processes the drug (pharmacokinetics, PK) and how the drug affects the body (pharmacodynamics, PD). These characteristics are essential for defining the appropriate dosage, administration schedule, and safety considerations.

3.1 Pharmacokinetics

Palifermin is administered as an intravenous (IV) bolus injection and exhibits linear pharmacokinetics, meaning that exposure increases proportionally with the dose.[16] Pharmacokinetic studies have been conducted in both healthy volunteers and patients with hematologic malignancies, revealing a unique and complex plasma concentration-time profile.

Following IV administration, palifermin concentrations display a distinct pattern. There is an initial, rapid decline where concentrations decrease by over 95% within the first 30 minutes post-dose. This is followed by an unusual phase where the concentration either plateaus or shows a slight increase between approximately 1 and 6 hours. Finally, a terminal decline phase ensues.[19] This triphasic profile is not typical of simple drug elimination and strongly suggests a process known as target-mediated drug disposition (TMDD). In this model, the initial rapid drop represents distribution from the central blood compartment. The subsequent plateau is likely caused by the drug binding with high affinity to its target, the KGF receptors on epithelial cells throughout the body. This binding acts as a temporary reservoir; as free drug is cleared from the plasma, drug dissociates from the receptors, causing the plasma concentration to stabilize before the final elimination phase begins.

Key pharmacokinetic parameters differ between cancer patients and healthy subjects. On average, the total body clearance (CL) of palifermin is two- to four-fold higher, and the volume of distribution at steady state (Vss) is approximately two-fold higher, in cancer patients compared to healthy individuals after a 60 mcg/kg dose.[21] These differences may reflect an altered baseline state of epithelial tissue or inflammatory conditions in cancer patients, which could affect receptor expression and drug binding.

Despite these differences in clearance and distribution, the elimination half-life (t1/2​) is remarkably consistent between the two populations, with an average of 4.5 hours and a range of 3.3 to 5.7 hours.[19] The relatively short half-life ensures that the drug does not accumulate in the body with the recommended regimen of three consecutive daily doses.[19]

Table 3.1: Summary of Key Pharmacokinetic Parameters in Healthy vs. Cancer Patient Populations

| Parameter | Healthy Volunteers | Cancer Patients | Source(s) |

| :--- | :--- | :--- | :--- |

| Elimination Half-life (t1/2​) | Average 4.5 hours (Range: 3.3–5.7) | Average 4.5 hours (Range: 3.3–5.7) | 19 |

| Total Body Clearance (CL) | Baseline | 2- to 4-fold higher than healthy volunteers | 21 |

| Volume of Distribution (Vss) | Baseline | ~2-fold higher than healthy volunteers | 21 |

3.2 Pharmacodynamics

The pharmacodynamic effect of palifermin is the direct biological response to the drug: the stimulation of epithelial cell proliferation. This has been quantitatively measured in clinical studies using the proliferation marker Ki67 in immunohistochemical staining of buccal mucosal biopsies from healthy subjects.[20]

These studies demonstrated a clear dose-dependent effect. Administration of palifermin at 40 mcg/kg/day IV for 3 days resulted in a three-fold or greater increase in Ki67 staining 24 hours after the third dose.[20] A single-dose study in healthy volunteers showed a dose-proportional increase in proliferation at 48 hours post-dosing across a range of 60 to 250 mcg/kg.[26]

The relationship between palifermin's PK and PD profiles provides the rationale for its specific dosing regimen. The short half-life of 4.5 hours means the drug is cleared from the system relatively quickly. However, the pharmacodynamic response—epithelial proliferation—takes time to manifest, becoming evident at 24 to 48 hours post-dose.[28] This temporal disconnect explains the necessity of administering daily doses for three consecutive days. This regimen ensures a sustained proliferative signal is delivered to the epithelial tissues, allowing sufficient time for the mucosal barrier to thicken and strengthen

before it is exposed to the cytotoxic insult of myeloablative therapy. A single dose would likely be insufficient to produce a robust and lasting protective effect.

4.0 Clinical Efficacy and Pivotal Trials

The clinical utility of palifermin was established through a rigorous clinical development program, highlighted by a landmark Phase 3 trial that demonstrated its profound efficacy in a specific high-risk population. However, subsequent studies also clearly delineated the boundaries of its effectiveness, revealing that its benefits are not universal across all settings of oral mucositis.

4.1 The Pivotal Phase 3 Trial in Autologous HSCT

The approval of palifermin was primarily based on the results of a large, multicenter, randomized, double-blind, placebo-controlled Phase 3 study published by Spielberger et al. in 2004.[11] This trial was designed to assess the efficacy and safety of palifermin in preventing severe oral mucositis in one of the highest-risk patient populations.

The study enrolled 212 patients with hematologic malignancies, such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, and leukemia, who were scheduled to undergo a highly myeloablative conditioning regimen followed by autologous hematopoietic stem cell transplantation (HSCT).[6] The conditioning regimen consisted of fractionated total-body irradiation (TBI) combined with high-dose chemotherapy (etoposide and cyclophosphamide), a combination known to cause severe OM in nearly all patients.[19] Patients were randomized in a 1:1 ratio to receive either palifermin at a dose of 60 mcg/kg/day or a matching placebo. The study drug was administered as an IV bolus for three consecutive days before the conditioning regimen and for three consecutive days after the stem cell infusion.[31]

The results were statistically significant and clinically compelling across multiple endpoints.

Table 4.1: Key Efficacy Endpoints from the Pivotal Phase 3 Trial (Spielberger et al., 2004)

| Efficacy Endpoint | Palifermin (n=106) | Placebo (n=106) | P-value | Source(s) |

| :--- | :--- | :--- | :--- | :--- |

| Incidence of WHO Grade 3/4 OM (%) | 63 | 98 | <0.001 | 31 |

| Median Duration of WHO Grade 3/4 OM (days) | 3 | 9 | <0.001 | 19 |

| Incidence of WHO Grade 4 OM (%) | 20 | 62 | <0.001 | 6 |

| Patient-Reported Soreness (AUC Score) | 29.0 | 46.8 | <0.001 | 6 |

| Median Opioid Use (Morphine Equivalents, mg) | 212 | 535 | <0.001 | 28 |

| Incidence of TPN Use (%) | 31 | 55 | <0.001 | 11 |

As detailed in Table 4.1, palifermin dramatically reduced the incidence of severe (WHO Grade 3 or 4) OM from 98% in the placebo group to 63%.[31] Even more strikingly, it reduced the incidence of the most debilitating form, Grade 4 OM (where patients are unable to swallow anything), by three-fold, from 62% to 20%.[6] Among all patients, the median number of days spent with severe OM was reduced from 9 days to just 3 days.[19]

These objective clinical benefits translated directly into improved patient-reported outcomes and reduced healthcare resource utilization. Patients receiving palifermin reported 54% less mouth and throat soreness, required less than half the amount of opioid analgesics for pain control, and were significantly less likely to require TPN for nutritional support.[6] A reduction in the average length of hospital stay was also noted (15.3 days vs. 17.3 days).[6]

4.2 Limitations of Efficacy: Settings of Ineffectiveness

The remarkable success of palifermin in the pivotal trial was not replicated in all clinical contexts, highlighting the specificity of its therapeutic window. Subsequent studies and prescribing information have established clear limitations on its use:

• Allogeneic HSCT: In patients undergoing allogeneic HSCT (receiving stem cells from a donor), palifermin was found to be ineffective at decreasing the incidence of severe mucositis.[14] This failure underscores the complex pathophysiology of OM in this setting. Unlike autologous HSCT where mucositis is primarily due to direct chemo/radiation toxicity, allogeneic HSCT introduces the additional complication of graft-versus-host disease (GVHD), an immune-mediated attack by donor cells on host tissues, including the oral mucosa. Palifermin's mechanism of stimulating epithelial repair may be insufficient to overcome or may be overwhelmed by this concurrent inflammatory and immunological assault.
• High-Dose Melphalan Conditioning: Palifermin is not recommended for use with conditioning regimens consisting of high-dose melphalan (e.g., 200 mg/m²), commonly used for multiple myeloma.[14] A postmarketing clinical trial failed to demonstrate a therapeutic benefit in this population, suggesting that the nature of the cytotoxic agent and its specific mechanism of mucosal damage influence palifermin's efficacy.
• Non-Hematologic (Solid) Malignancies: The safety and efficacy of palifermin have not been established in patients with solid tumors.[2] While a Phase 3 trial was conducted in patients with locally advanced head and neck cancer, a population that suffers immensely from mucositis, the results have not been widely published or led to an expanded indication, likely due to the safety concerns regarding potential tumor stimulation in these epithelial-derived cancers.[37]

In summary, the clinical evidence paints a clear picture of palifermin as a highly potent but specialized therapeutic agent. Its efficacy is profoundly context-dependent, providing maximal benefit in settings of intense, predictable, and direct cytotoxic mucosal injury, as exemplified by TBI-based conditioning for autologous HSCT.

5.0 Safety and Tolerability Profile

The safety profile of palifermin is well-characterized and is intrinsically linked to its mechanism of action. Most common adverse events are considered on-target, exaggerated pharmacological effects resulting from the systemic stimulation of epithelial cells. While generally well-tolerated, there are important warnings and precautions, most notably the theoretical risk of stimulating tumor growth.

5.1 Common and Serious Adverse Reactions

The most frequently reported adverse reactions are mucocutaneous in nature, typically mild to moderate in severity, and transient, resolving after the treatment course is complete.[11] The median time to onset for skin-related toxicities is approximately 6 days after the first dose, with a median duration of 5 days.[34]

Common Adverse Reactions (incidence ≥20% and at least 5% greater than placebo) include [28]:

• Skin Toxicities: Rash (up to 62% of patients), pruritus (itching), erythema (redness), and edema (swelling).
• Oral Toxicities: Oral or perioral dysesthesia (altered sensation such as numbness or tingling), alteration of taste, tongue thickening, and tongue discoloration.
• Systemic Effects: Fever and arthralgia (joint pain).
• Laboratory Abnormalities: Transient, asymptomatic elevations in serum amylase and lipase are common. Grade 3 or 4 elevations in amylase and lipase were observed in 38% and 11% of palifermin-treated patients, respectively.[6]

Serious Adverse Reactions and Warnings:

• Potential for Stimulation of Tumor Growth: This is the most critical warning associated with palifermin. The drug is not indicated for use in patients with non-hematologic malignancies. Because the KGF receptor is expressed on many epithelial cell types, there is a theoretical concern that palifermin could promote the growth of KGF receptor-expressing solid tumors (carcinomas). This concern is supported by preclinical data showing that palifermin can enhance the growth of human epithelial tumor cell lines in vitro at concentrations more than 15 times higher than average therapeutic levels, and can increase the growth rate of a human carcinoma in a mouse xenograft model.[2] This risk has significantly limited its investigation and application in solid tumor settings.
• Ophthalmologic Effects: KGF receptors are known to be expressed on the epithelial cells of the lens of the eye. While a definitive causal link has not been established, a postmarketing safety study observed a numerically higher incidence of cataracts in patients who received Kepivance (48%) compared to a control population (29%) at a 12-month follow-up.[20] Therefore, a potential cataractogenic effect of palifermin cannot be excluded.
• Hypersensitivity Reactions: While rare, serious hypersensitivity reactions can occur. Postmarketing reports include cases of anaphylaxis and one instance of life-threatening respiratory distress.[20] Mild to moderate allergic reactions have been reported more frequently.[25] Resuscitation equipment should be available during administration as a precaution.

Table 5.1: Incidence of Common Adverse Reactions from Clinical Trials (Palifermin vs. Placebo)

| Adverse Reaction | Palifermin (%) (n=409) | Placebo (%) (n=241) |

| :--- | :--- | :--- |

| Rash | 62 | 50 |

| Fever | 39 | 34 |

| Pruritus | 35 | 24 |

| Erythema | 32 | 22 |

| Edema | 28 | 21 |

| Elevated Serum Lipase (All Grades) | 28 | 23 |

| Mouth/Tongue Thickness or Discoloration | 17 | 8 |

| Taste Alteration | 16 | 8 |

| Dysesthesia | 12 | 7 |

| Arthralgia | 10 | 5 |

Data derived from clinical trial experience reported in prescribing information.34

5.2 Contraindications and Use in Specific Populations

• Contraindications: Palifermin is contraindicated in patients with a known history of hypersensitivity to E. coli-derived proteins, palifermin itself, or any of the excipients in the formulation (mannitol, sucrose, L-histidine, polysorbate 20).[1]
• Pregnancy: Palifermin is classified as Pregnancy Category C. Animal studies have shown embryotoxicity, including increased post-implantation loss and skeletal variations, at doses higher than the recommended human dose. There are no adequate and well-controlled studies in pregnant women, and the drug may cause fetal harm.[1]
• Lactation: It is not known whether palifermin is excreted in human milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 2 weeks following the final dose.[34]
• Pediatric Use: Initial approval did not establish safety and efficacy in children. However, the label was later updated to state that use in pediatric patients aged 1 to 16 years is supported by evidence from adult studies and a Phase 1 dose-escalation PK and safety study in 27 pediatric patients. The adverse event profile in children was similar to that observed in adults.[28]
• Geriatric Use: Clinical studies did not include sufficient numbers of patients aged 65 and over to determine if they respond differently from younger subjects.[28]

6.0 Dosage, Administration, and Drug Interactions

The safe and effective use of palifermin is highly dependent on strict adherence to its specific dosing, timing, and administration guidelines. These protocols are derived directly from the drug's clinical pharmacology and are designed to maximize its protective effects while minimizing potential harm.

6.1 Recommended Dosage and Administration Schedule

The recommended dosage of palifermin is 60 mcg/kg/day, administered as an intravenous (IV) bolus injection.[16] The treatment course consists of a total of six doses, administered in two distinct phases relative to the myelotoxic therapy.

The administration schedule is critically important and is detailed in Table 6.1.

Table 6.1: Recommended Dosing and Administration Schedule for Palifermin

| Dosing Period | Dose Number | Timing of Administration | Critical Notes | Source(s) |

| :--- | :--- | :--- | :--- | :--- |

| Pre-Myelotoxic Therapy | Dose 1 | 3 days before therapy | Administered on 3 consecutive days. | 33 |

| | Dose 2 | 2 days before therapy | | |

| | Dose 3 | 1 day before therapy | Must be given 24 to 48 hours BEFORE start of myelotoxic therapy. | 33 |

| Myelotoxic Therapy Window | - | - | DO NOT ADMINISTER Palifermin within 24 hours before, during, or 24 hours after myelotoxic chemotherapy. | 16 |

| Post-Myelotoxic Therapy | Dose 4 | Day of HSCT | Administer on the day of hematopoietic stem cell infusion, after the infusion is complete. Must be at least 7 days after Dose 3. | 33 |

| | Dose 5 | Day after HSCT | Administered on 3 consecutive days. | 33 |

| | Dose 6 | 2 days after HSCT | | |

The precise timing of administration is paramount. The rationale for the 24-hour avoidance window around chemotherapy is based on fundamental pharmacology. Palifermin stimulates epithelial cells to enter a state of rapid proliferation. Myelotoxic chemotherapy targets and kills rapidly dividing cells. If palifermin is administered too close to chemotherapy, it can "prime" the healthy mucosal cells, making them more sensitive and vulnerable to the cytotoxic effects of the chemotherapy. This interaction can paradoxically lead to an increase in the severity and duration of oral mucositis, negating the drug's intended benefit.[25]

6.2 Preparation and Handling

Palifermin is supplied as a sterile, white, preservative-free, lyophilized powder in a single-use vial.[19] The current formulation contains 5.16 mg of palifermin per vial.[44] To prepare for administration, the powder must be reconstituted with 1.2 mL of Sterile Water for Injection, USP, to yield a final solution with a concentration of 5 mg/mL and a pH of 6.5.[19] During reconstitution, the vial should be swirled gently; vigorous shaking or agitation should be avoided.[28] The reconstituted solution should be clear, colorless, and visually inspected for particulate matter before use. It should not be filtered during preparation or administration.[28]

The reconstituted solution contains no preservatives and should be used immediately. If immediate use is not possible, it may be stored refrigerated at 2°C to 8°C in its original carton to protect from light for up to 24 hours. Before injection, the refrigerated solution should be allowed to reach room temperature for a maximum of 1 hour, while still protected from light. Any solution left at room temperature for more than 1 hour must be discarded.[28]

6.3 Drug Interactions

Formal drug interaction studies are limited, but two clinically significant interactions are well-established.

• Heparin: Palifermin has been shown to bind to both unfractionated and low-molecular-weight heparins in vitro.[20] Co-administration of heparin with palifermin can lead to a pronounced pharmacokinetic interaction, resulting in a 4- to 5-fold increase in palifermin systemic exposure (AUC).[46] Counterintuitively, this significant PK change does not appear to alter the pharmacodynamic effect of palifermin (as measured by epithelial proliferation) or lead to increased safety issues.[46] This suggests that the biological response system is saturated at therapeutic concentrations, and the increased plasma levels do not translate to a proportional increase in effect. Despite the lack of a PD interaction, to avoid any potential physical incompatibility, it is a critical nursing consideration that any IV line maintained with heparin must be flushed with 0.9% sodium chloride solution both prior to and following palifermin administration.[28]
• Chemotherapeutic Agents: Beyond the critical timing interaction, the therapeutic efficacy of palifermin may be decreased when used in combination with a wide array of cytotoxic agents, including cyclophosphamide, cytarabine, capecitabine, and many others.[15] This underscores the importance of adhering to the approved indication and dosing schedule.

7.0 Regulatory and Commercial History

The journey of palifermin from development to market provides a compelling case study on the lifecycle of a niche biologic therapeutic, illustrating how clinical success does not always translate to straightforward commercial success.

7.1 Development and Regulatory Approval

Palifermin was developed by the biotechnology company Amgen Inc..[24] Recognizing the significant unmet need for a therapy to combat severe oral mucositis, the company advanced the drug through clinical trials. Following the successful pivotal Phase 3 study, Amgen submitted a Biologics License Application (BLA) to the U.S. FDA in June 2004.[47] The application was granted a priority review, a designation reserved for therapies that represent a significant improvement in the treatment, diagnosis, or prevention of a serious condition. On December 15, 2004, the FDA approved Kepivance® (palifermin) for its specific indication in patients with hematologic malignancies.[13]

Following its success in the United States, Amgen pursued global registration. The European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in July 2005.[10] The European Commission subsequently granted marketing authorization for Kepivance in the European Union on October 25, 2005, for a similar indication.[49]

7.2 Acquisition and Market Withdrawal

Despite its clinical value and regulatory approvals, palifermin's trajectory shifted. On September 15, 2008, Amgen announced an agreement to divest Kepivance, along with other products, to Biovitrum AB, a Swedish pharmaceutical company that would later become Swedish Orphan Biovitrum (Sobi).[51] The deal closed on December 16, 2008.[53] This move suggested that the product, with its narrow indication and specialized patient population, was a better strategic fit for a company focused on orphan and rare diseases rather than a large biotechnology firm pursuing blockbuster therapies. Sobi later acquired additional clinical data from Amgen in 2013, related to trials in head and neck cancer, to explore potential new indications.[38]

The commercial challenges for this niche product became more apparent over time. On April 1, 2016, the European Commission officially withdrew the marketing authorization for Kepivance in the EU.[55] This action was taken at the formal request of Sobi, the marketing authorization holder, which cited "commercial reasons" for its decision to permanently discontinue marketing the product in Europe.[55]

This history demonstrates that even a highly effective, first-in-class therapy can face significant commercial headwinds. The combination of a very specific and limited patient population, a high acquisition cost associated with biologics, and potential reimbursement complexities likely made the product commercially non-viable in the diverse European market. Palifermin remains available in the United States, where it is marketed by Sobi North America, but its story serves as a powerful example of how market forces can ultimately determine the global availability of a medically important therapy.[56]

8.0 Pharmacoeconomic Analysis and Place in Therapy

The value proposition of palifermin is complex, with its clinical benefits weighed against its acquisition cost and its specific role within the broader landscape of oral mucositis management. Its place in therapy is well-defined by clinical practice guidelines, which position it as a specialized tool for high-risk scenarios.

8.1 Pharmacoeconomic Considerations

The cost-effectiveness of palifermin has been a subject of analysis, with studies yielding different conclusions based on the clinical context and methodologies used. This apparent conflict highlights how the economic value of the drug is directly tied to the baseline risk of the patient population being treated.

An early economic analysis based on data from the pivotal Phase 3 trial projected significant cost savings. This study estimated that by reducing the incidence of severe OM and its downstream consequences—such as febrile neutropenia, bacteremia, use of TPN, and length of hospital stay—palifermin prophylaxis could lead to a mean hospital cost saving of approximately $14,943 per patient. However, a critical limitation of this analysis was that it did not include the acquisition cost of palifermin itself, which had not yet been determined.[58]

In contrast, a later retrospective, single-center study examined the economic impact in patients undergoing autologous HSCT with non-TBI-based conditioning regimens (e.g., high-dose melphalan for myeloma), which are generally less mucotoxic. This study found that while palifermin significantly reduced the use of patient-controlled analgesia (PCA) for pain—a surrogate for severe mucositis—it was associated with significantly higher median total transplant charges (e.g., an increase from $143,200 to $167,820 for myeloma patients). The analysis concluded that palifermin came at an additional cost of $5,500 to $14,000 per day of PCA avoided.[4] Another analysis calculated an Incremental Cost-Effectiveness Ratio (ICER) of $1,374 per hospitalized day avoided, a figure that must be weighed against institutional thresholds for cost-effectiveness.[61]

These findings are not necessarily contradictory. They demonstrate that the pharmacoeconomic benefit of palifermin is greatest when used in the highest-risk populations. In a setting like the pivotal trial, where the incidence of severe OM in the placebo group was 98%, the drug's ability to prevent costly complications is maximized and can more easily offset its price. In lower-risk settings, the absolute clinical benefit is smaller, and the drug's acquisition cost becomes the dominant factor in the economic equation.

8.2 Place in Clinical Practice Guidelines

Palifermin's role is firmly established within major clinical practice guidelines, which universally recognize its efficacy but restrict its recommendation to its specific, evidence-backed indication. This creates a risk-stratified, tiered approach to OM management.

• Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO): As the leading guideline-developing body for mucositis, MASCC/ISOO provides a strong recommendation for the use of palifermin to prevent oral mucositis in patients with hematologic malignancies receiving high-dose chemotherapy and TBI, followed by autologous HSCT.[62] This recommendation is based on the high-quality evidence from the pivotal randomized controlled trial.
• American Society of Clinical Oncology (ASCO): ASCO guidelines align with this, recommending palifermin for patients undergoing autologous stem-cell transplantation for a hematologic malignancy conditioned with a TBI-based regimen.[62]
• National Comprehensive Cancer Network (NCCN): NCCN task force reports identify palifermin as one of the few effective preventive strategies for OM specifically in the setting of hematopoietic stem cell transplantation.[5]

These guidelines position palifermin as a top-tier intervention for a specific, high-risk job, while other, more general strategies form the foundation of care for all patients.

Table 8.1: Select Guideline Recommendations for Oral Mucositis Prevention

| Intervention | Patient Population / Setting | Guideline Body | Recommendation Level | Source(s) |

| :--- | :--- | :--- | :--- | :--- |

| Basic Oral Care Protocol | All cancer treatment modalities | MASCC/ISOO | Suggestion | 64 |

| Oral Cryotherapy | Patients receiving bolus 5-FU or high-dose melphalan | NCCN, Cancer Care Ontario | Recommendation/Standard | 5 |

| Palifermin | Autologous HSCT for hematologic malignancy with TBI-based conditioning | MASCC/ISOO, ASCO, NCCN | Recommendation | 62 |

| Low-Level Laser Therapy (Photobiomodulation) | HSCT with high-dose chemotherapy (+/- TBI) | NCI PDQ Summary | Recommendation (Level of Evidence: IV) | 67 |

| Chlorhexidine Rinse | Head and Neck cancer patients receiving radiation | MASCC/ISOO | Suggestion AGAINST use | 64 |

As shown in Table 8.1, palifermin does not replace but rather complements other management strategies. Basic oral care, including gentle brushing and bland rinses (e.g., saline, sodium bicarbonate), is a foundational suggestion for all patients.[66] Oral cryotherapy (sucking on ice chips) is a simple, effective intervention recommended for specific chemotherapy agents like bolus 5-fluorouracil or high-dose melphalan, where it is thought to work by causing local vasoconstriction and reducing drug delivery to the oral mucosa.[5] Emerging therapies like low-level laser therapy (LLLT) are also gaining traction in guidelines.[67] In contrast, some interventions like chlorhexidine mouthwash are recommended against in certain settings due to lack of efficacy.[64] Palifermin's place is thus clearly defined as a powerful but specialized agent reserved for patients facing the highest risk of severe, life-altering mucositis.

9.0 Patient Counseling and Management Considerations

Effective communication with patients is essential for the safe and successful use of palifermin. Counseling should focus on the purpose of the medication, the administration schedule, management of expected side effects, and awareness of serious risks.

9.1 Key Counseling Points

Healthcare providers should discuss the following points with patients scheduled to receive palifermin:

• Purpose of Medication: Patients should understand that palifermin is not a treatment for their cancer but a supportive care medication. Its purpose is to help prevent or reduce the severity and duration of painful mouth and throat sores that are a common side effect of their high-dose chemotherapy and radiation regimen.[71]
• Administration Schedule: It is crucial to explain that the drug is given as an intravenous (IV) injection according to a strict 6-dose schedule: three doses before their main therapy starts and three doses after their stem cell transplant. The importance of adhering to this schedule and not missing appointments should be emphasized.[72]
• Common Side Effects: Patients should be proactively counseled about the most common side effects to manage expectations and reduce anxiety. It can be helpful to frame these as predictable, on-target effects. For example, clinicians can explain that because the medicine works by stimulating the growth of skin-like cells, patients may notice temporary changes such as:
• Skin changes: A rash, redness, or itching on the skin.[33]
• Mouth and tongue changes: A feeling of thickness in the tongue, changes in tongue color, altered taste, or a numb or tingling sensation in or around the mouth.[34]
• Other common effects: Joint pain or fever.[16]

It should be stressed that these effects are typically mild to moderate and temporary.28

• Serious Risks and Precautions:
• Allergic Reactions: Patients must be instructed to report any signs of a potential allergic reaction immediately, including hives, severe rash, difficulty breathing or swallowing, wheezing, or swelling of the face, lips, tongue, or throat.[72]
• Reproductive Health: The potential for fetal harm must be discussed. Patients of reproductive potential should be advised to use effective methods of contraception during treatment and for at least two weeks after the final dose. The potential for impaired fertility in both females and males should also be mentioned. Women should be counseled not to breastfeed during treatment and for at least two weeks after the last dose.[34]
• Tumor Growth Risk: Patients should be informed that palifermin is only for their type of blood cancer and has not been established as safe for other cancer types, due to a theoretical risk of stimulating the growth of other tumors.[33]
• When to Contact a Healthcare Provider: Patients should be given clear instructions on when to seek medical attention, such as for a fever of 100.5°F (38.0°C) or higher, chills, trouble breathing, or any side effect that becomes severe, is not relieved by prescribed medication, or is otherwise concerning.[73]

By providing this comprehensive information, healthcare teams can empower patients to be active participants in their care, improve adherence to the treatment plan, and ensure that potential adverse events are identified and managed promptly.

10.0 Conclusion and Future Directions

Palifermin (Kepivance®) occupies a unique and important place in the supportive care armamentarium for oncology. It is a triumph of rational drug design and clinical research—a bioengineered, stability-enhanced growth factor that proved in a landmark trial to be a highly effective, targeted therapy for preventing one of the most debilitating toxicities of cancer treatment.[19] Its ability to significantly reduce the incidence, duration, and severity of severe oral mucositis in patients with hematologic malignancies undergoing myeloablative therapy with autologous stem cell support is undisputed and has established a new standard of care for this high-risk population.[11]

The risk-benefit profile of palifermin is well-defined. The primary benefit is the profound reduction in morbidity, leading to less pain, decreased need for opioid analgesia and parenteral nutrition, and improved quality of life during a grueling treatment course.[6] The risks are largely predictable and manageable, consisting primarily of transient, on-target mucocutaneous side effects. The most significant risk remains the theoretical potential for stimulation of non-hematologic tumors, a mechanism-based concern that has rightfully restricted its indication and curtailed its investigation in solid tumor settings where mucositis is also a major clinical problem.[34]

The story of palifermin is ultimately a microcosm of the complex landscape of modern specialty pharmaceuticals. It demonstrates that profound clinical efficacy alone is not sufficient to guarantee broad clinical application or widespread commercial success. Its therapeutic utility is confined by its mechanism-based safety profile, its value proposition is complicated by a pharmacoeconomic profile that is highly dependent on the patient's baseline risk, and its global market presence has been shaped by commercial forces that led to its withdrawal from the European market.[55]

Future directions for palifermin appear limited. While off-label use in other high-risk settings has been explored in case reports, the overarching concern about tumor stimulation remains a formidable barrier to conducting the large-scale trials needed to expand its indication.[2] The lack of biosimilar development further suggests a market that is perceived as too small or complex to incentivize competition.[78] Therefore, palifermin is likely to remain what it is today: a powerful, effective, but exceptionally niche therapeutic agent, reserved for a specific group of patients facing the highest risk of severe cytotoxic injury. Its journey serves as a crucial lesson on the intricate interplay between scientific innovation, clinical need, safety, cost, and market dynamics that determines the ultimate impact of a medicine.

Works cited

1. Palifermin: A keratinocyte growth factor for oral mucositis, accessed June 19, 2025, http://www.bioline.org.br/pdf?ph05090
2. Palifermin Use for the Prevention of Chemotherapy-Induced Oral Mucositis in Anal Cancer: A Case Report - Journal of Hematology Oncology Pharmacy, accessed June 19, 2025, https://jhoponline.com/issue-archive/2013-issues/june-2013-vol-3-no-2/palifermin-use-for-the-prevention-of-chemotherapy-induced-oral-mucositis-in-anal-cancer-a-case-report
3. Natural agents in the management of oral mucositis in cancer patients-systematic review, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6107930/
4. Pharmacoeconomic analysis of palifermin to prevent mucositis ..., accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4063211/
5. NCCN Task Force Report. prevention and management of mucositis in cancer care - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/18289497/
6. Phase 3 Data Show Palifermin Improves Patient Reported ... - Amgen, accessed June 19, 2025, https://www.amgen.com/newsroom/press-releases/2003/12/phase-3-data-show-palifermin-improves-patient-reported-outcomes-in-cancer-patients-and-helps-reduce-hospitalizations-and-healthcare-resources
7. European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients - Bionity, accessed June 19, 2025, https://www.bionity.com/en/news/49901/european-commission-approves-kepivance-tm-palifermin-for-oral-mucositis-in-cancer-patients.html
8. Efficacy of Palifermin in the Hematopoietic Stem Cell Transplant Setting - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4093413/
9. Oral Mucositis: Update on Prevention and Management Strategies - U.S. Pharmacist, accessed June 19, 2025, https://www.uspharmacist.com/article/oral-mucositis-update-on-prevention-and-management-strategies-12403
10. Kepivance(TM) (palifermin) Receives Positive Regulatory Opinion for Approval in Europe, accessed June 19, 2025, https://www.amgen.com/newsroom/press-releases/2005/07/kepivancetm-palifermin-receives-positive-regulatory-opinion-for-approval-in-europe
11. Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers | Request PDF, accessed June 19, 2025, https://www.researchgate.net/publication/8127989_Palifermin_for_Oral_Mucositis_after_Intensive_Therapy_for_Hematologic_Cancers
12. Palifermin for management of treatment-induced oral mucositis in cancer patients - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2726051/
13. FDA Approves Kepivance for Severe Oral Mucositis in Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published in This Week's New England Journal of Medicine, accessed June 19, 2025, https://investors.amgen.com/news-releases/news-release-details/fda-approves-kepivance-severe-oral-mucositis-cancer-patients/
14. Kepivance - FEPBlue, accessed June 19, 2025, https://www.fepblue.org/-/media/PDFs/Medical-Policies/2024/June/June-2024-Pharmacy-Policies/Remove--Replace/521008-Kepivance-palifermin.pdf
15. Palifermin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/drugs/DB00039
16. Palifermin - Wikipedia, accessed June 19, 2025, https://en.wikipedia.org/wiki/Palifermin
17. What is the mechanism of Palifermin? - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-palifermin
18. PALIFERMIN - Inxight Drugs - ncats, accessed June 19, 2025, https://drugs.ncats.io/drug/palifermin
19. Kepivance™ (palifermin) - Amazon S3, accessed June 19, 2025, https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00039.pdf?1265922805
20. Kepivance, INN-palifermin, accessed June 19, 2025, https://ec.europa.eu/health/documents/community-register/2012/20121025124771/anx_124771_en.pdf
21. Kepivance™ (palifermin) - accessdata.fda.gov, accessed June 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125103lbl.pdf
22. Palifermin - brand name list from Drugs.com, accessed June 19, 2025, https://www.drugs.com/ingredient/palifermin.html
23. Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4118166/
24. What is Palifermin used for? - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/article/what-is-palifermin-used-for
25. PRODUCT MONOGRAPH PrKEPIVANCE® (palifermin) Sterile, Lyophilized Powder for Reconstitution (6.25 mg/vial) Intravenous Use Only, accessed June 19, 2025, https://pdf.hres.ca/dpd_pm/00028444.PDF
26. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/16765144/
27. Pharmacokinetics (PK) of 2 Dosing Regimens of Palifermin in Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemoradiotherapy and Hematopoietic Stem Cell Transplantation (HSCT). | Blood, accessed June 19, 2025, https://ashpublications.org/blood/article/106/11/5294/123797/Pharmacokinetics-PK-of-2-Dosing-Regimens-of
28. Palifermin Monograph for Professionals - Drugs.com, accessed June 19, 2025, https://www.drugs.com/monograph/palifermin.html
29. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. | Meso Scale Discovery, accessed June 19, 2025, https://www.mesoscale.com/en/references/2006/pharmacokinetics
30. Palifermin for oral mucositis after intensive therapy for hematologic cancers. | Profiles RNS, accessed June 19, 2025, https://profiles.umassmed.edu/profile/54485583
31. Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers, accessed June 19, 2025, https://cdr.lib.unc.edu/concern/articles/h128nq00h?locale=en
32. Palifermin for oral mucositis after intensive therapy for hematologic ..., accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/15602019/
33. HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Sobi, accessed June 19, 2025, https://www.sobi.com/sites/sobi/files/2023-10/Kepivance%20Prescribing%20Information%20July%202023.pdf
34. These highlights do not include all the information needed to use ..., accessed June 19, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=426f6e64-2c20-4a61-6d65-7320426f6e64
35. Pediatric Focused Safety Review: Kepivance (palifermin) - FDA, accessed June 19, 2025, https://www.fda.gov/media/100492/download
36. Kepivance, INN-palifermin, accessed June 19, 2025, https://ec.europa.eu/health/documents/community-register/2016/20160322134570/anx_134570_en.pdf
37. Solid Tumors Completed Phase 3 Trials for Palifermin (DB00039) | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/indications/DBCOND0029860/clinical_trials/DB00039?phase=3&status=completed
38. Sobi acquires full rights for Kineret® and additional clinical data for Kepivance® from Amgen, accessed June 19, 2025, https://www.sobi.com/en/press-releases/sobi-acquires-full-rights-kineretr-and-additional-clinical-data-kepivancer-amgen
39. Palifermin (Kepivance) use while Breastfeeding - Drugs.com, accessed June 19, 2025, https://www.drugs.com/breastfeeding/palifermin.html
40. Palifermin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed June 19, 2025, https://www.ncbi.nlm.nih.gov/books/n/lactmed/palifermin/
41. Kepivance (palifermin) dosing, indications, interactions, adverse effects, and more, accessed June 19, 2025, https://reference.medscape.com/drug/kepivance-palifermin-342271
42. Palifermin, accessed June 19, 2025, http://static.ons.org/Online-Courses/ChemoRenewal/chmo05_palifermin.html
43. Kepivance Dosage Guide - Drugs.com, accessed June 19, 2025, https://www.drugs.com/dosage/kepivance.html
44. Drug Shortage Detail: Palifermin Injection - ASHP, accessed June 19, 2025, https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=919
45. Palifermin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed June 19, 2025, https://www.drugs.com/dosage/palifermin.html
46. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/25880826/
47. Kepivance (palifermin) FDA Approval History - Drugs.com, accessed June 19, 2025, https://www.drugs.com/history/kepivance.html
48. Palifermin (marketed as Kepivance) - FDA, accessed June 19, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/palifermin-marketed-kepivance
49. palifermin | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed June 19, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6954
50. European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant - Amgen's investor, accessed June 19, 2025, https://investors.amgen.com/news-releases/news-release-details/european-commission-approves-kepivancetm-palifermin-oral/
51. Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen, accessed June 19, 2025, https://www.amgen.com/newsroom/press-releases/2008/09/biovitrum-to-acquire-kepivancer-and-stemgenr-and-exclusively-license-kineretr-from-amgen
52. Biovitrum to Acquire Kepivance® and Stemgen® and Exclusively ..., accessed June 19, 2025, https://www.sobi.com/en/press-releases/biovitrum-acquire-kepivancer-and-stemgenr-and-exclusively-licensekineretr-amgen
53. Biovitrum and Amgen Announce Close of Product Acquisition Deal - Sobi, accessed June 19, 2025, https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729
54. Sobi Capital Markets Day, accessed June 19, 2025, https://www.sobi.com/sites/sobi/files/2020-01/Sobi%20Capital%20Markets%20Day%20Nov%202013%20(1).pdf
55. Kepivance | European Medicines Agency (EMA), accessed June 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance
56. KEPIVANCE® (palifermin) Injection, accessed June 19, 2025, https://www.kepivance.com/
57. Our Medicines | Sobi North America, accessed June 19, 2025, https://www.sobi.com/usa/en/who-we-are/our-medicines
58. Palifermin Reduces Estimated Downstream Costs of Autologous ..., accessed June 19, 2025, https://ashpublications.org/blood/article/104/11/2191/110508/Palifermin-Reduces-Estimated-Downstream-Costs-of
59. Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/6257518_Economic_Impact_of_Palifermin_on_the_Costs_of_Hospitalization_for_Autologous_Hematopoietic_Stem-Cell_Transplant_Analysis_of_Phase_3_Trial_Results
60. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/24607557/
61. Cost-effectiveness analysis of palifermin in prevention of severe oral mucositis among patients undergoing allogeneic hematopoietic stem cell transplantation - Simul Europe ePosters, accessed June 19, 2025, http://simul-europe.com/2017/mascc/Files/(dpon@westernu.edu)Palifermin%20Cost%20Effectiveness%20Analysis%20MASCC%202017%20170509.pdf
62. Palifermin (Kepivance) - Medical Clinical Policy Bulletins - Aetna, accessed June 19, 2025, https://www.aetna.com/cpb/medical/data/800_899/0851.html
63. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/262046870_MASCCISOO_Clinical_Practice_Guidelines_for_the_Management_of_Mucositis_Secondary_to_Cancer_Therapy
64. MASCC/ISOO clinical practice guidelines for the management of ..., accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4164022/
65. NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care in - JNCCN, accessed June 19, 2025, https://jnccn.org/abstract/journals/jnccn/6/S1/article-pS-1.xml
66. Symptom Management Guidelines: ORAL MUCOSITIS Focused Health Assessment - BC Cancer, accessed June 19, 2025, http://www.bccancer.bc.ca/nursing-site/documents/12.%20oral%20mucositis.pdf
67. Oral Complications (PDQ®) - National Cancer Institute, accessed June 19, 2025, https://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq
68. Oral mucositis - self-care: MedlinePlus Medical Encyclopedia, accessed June 19, 2025, https://medlineplus.gov/ency/patientinstructions/000047.htm
69. Oral Mucositis - Cancer Care Ontario, accessed June 19, 2025, https://www.cancercareontario.ca/en/system/files_force/symptoms/MucositisAlgorithm.pdf?download=1
70. Mucositis: Types, Symptoms & Treatment - Cleveland Clinic, accessed June 19, 2025, https://my.clevelandclinic.org/health/diseases/24181-mucositis
71. Palifermin | Leukemia and Lymphoma Society, accessed June 19, 2025, https://www.lls.org/drug/palifermin
72. Palifermin injection: Uses & Side Effects - Cleveland Clinic, accessed June 19, 2025, https://my.clevelandclinic.org/health/drugs/20656-palifermin-injection
73. Palifermin | Tahoe Forest Health System, accessed June 19, 2025, https://www.tfhd.com/cancer-center/drug-dictionary/palifermin/
74. Palifermin | Memorial Sloan Kettering Cancer Center, accessed June 19, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/palifermin
75. Palifermin - Green Valley Orthopedics, accessed June 19, 2025, https://gvortho.com/patient-information/patient-education/health-library/?DOCHWID=a605017
76. Palifermin | Memorial Sloan Kettering Cancer Center, accessed June 19, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/palifermin?msk_tools_print=pdf
77. Palifermin (Other Names: Kepivance) | UPMC Hillman Cancer Center, accessed June 19, 2025, https://hillman.upmc.com/patients/community-support/education/chemotherapy-drugs/palifermin
78. Are there any biosimilars available for Palifermin? - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/article/are-there-any-biosimilars-available-for-palifermin